Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Citation Manager Formats
Make Comment
See Comments
This article has a correction. Please see:

Article Information
- Received August 17, 2017
- Accepted in final form October 3, 2017
- First Published December 28, 2017.
Author Disclosures
- Maryam Nakhaei-Nejad, PhD,
- David Barilla, Dip,
- Chieh-Hsin Lee, BSc,
- Gregg Blevins, MD and
- Fabrizio Giuliani, MD
- Maryam Nakhaei-Nejad, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David Barilla, Dip,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Chieh-Hsin Lee, BSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gregg Blevins, MD and
Served on Advisory boards for Biogen Idec, Teva Pharmaceuticals, Novartis, Genzyme, Roche and EMD Serono/Merck from 2006-present
NONE
Received travel funding through Biogen Idec, Teva Pharmaceuticals, Novartis, Genzyme, Roche and EMD Serono/Merck from 2006-present
NONE
NONE
NONE
Self-employed
Have received consulting fees from Biogen Idec, Teva Pharmaceuticals, Novartis, Genzyme, Roche and EMD Serono/Merck from 2006-present
NONE
NONE
NONE
NONE
Canadian Institute for Health Research, Alberta Innovates, Canadian Foundation for Innovation
NONE
Multiple Sclerosis Society of Canada
NONE
NONE
NONE
NONE
NONE
NONE
- Fabrizio Giuliani, MD
(1)Alberta MS Network (non-profit)
NONE
(1)Merck-Serono, honoraria (2)Biogen, honoraria (3)Genzyme, honoraria (4)Roche, honoraria
NONE
NONE
NONE
NONE
(1)Merck-Serono (2)Biogen (3)Genzyme (4)Roche
NONE
NONE
NONE
(1)Biogen Canada
(1)Alberta Ministry of Innovation and Advanced Education,AE-2014-0065, Principal Investigator,4 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Correspondence to Dr. Giuliani: fabrizio.giuliani{at}ualberta.ca
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.